Keyword: Endo

India's Aurobindo has submitted a $1.6 billion offer for Novartis' generic dermatology assets in the U.S., according to Livemint.

AbbVie scored a major reduction of damages in a retrial of an AndroGel liability case brought by plaintiff Jesse Mitchell.

Endo, Teva and a Japanese drugmaker have agreed to fork over more than $270 million to resolve a class-action suit over Lidoderm.

Drugmakers haven't been able to reach a settlement with the cities and counties suing them over the opioid epidemic.

As opioid scrutiny intensifies around the country, Mallinckrodt has received another subpoena seeking info about its sales of the powerful painkillers.

Hundreds of cities and counties have sued to hold opioid makers accountable for the addiction epidemic. Now the feds are getting involved.

The court overseeing testosterone lawsuits has stayed all proceedings relating to Endo and GSK so the companies can work to settle their cases.

Purdue made a splash with its plans to stop marketing opioids this week, but Endo, Teva, Allergan and J&J had already quit.

Kroger and other grocery chains are suing Mylan, Teva, Endo and many other companies for an "overarching conspiracy" to artificially inflate prices.

Downward pricing pressure has dogged the generics industry for almost two years, but company executives say things are looking up.